Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 23;24(50):9285-9289.
doi: 10.1021/acs.orglett.2c03861. Epub 2022 Dec 14.

Total Synthesis of Pargamicin A

Affiliations

Total Synthesis of Pargamicin A

Yassin M Elbatrawi et al. Org Lett. .

Abstract

We report the total synthesis and configurational assignment of pargamicin A, a highly oxidized nonribosomal peptide that potently inhibits the growth of drug-resistant bacteria. Our synthetic approach relies on late-stage piperazine ring formation and careful selection of condensation reagents to assemble the densely substituted hexapeptide backbone. This work enables the synthesis of pargamicin congeners for the development of structure-activity relationships and informs strategies for accessing other sterically congested piperazic acid-containing natural products.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Structures of pargamicins A-D (PrgA-D; 1-4). Residue abbreviations for PrgA provided in blue.
Figure 2.
Figure 2.
Late-stage Piz formation approach to PrgA (1).
Figure 3.
Figure 3.
Screening of macrocyclization conditions.
Scheme 1.
Scheme 1.
Synthesis of γ-OH-d-Piz precursor 6.
Scheme 2.
Scheme 2.
Synthesis of γ-OH-d-Piz precursor 6.
Scheme 3.
Scheme 3.
Total synthesis of PrgA (1).

References

    1. Murray CJL et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 2022, 399, 629–655. - PMC - PubMed
    1. World Health Organisation (May 26, 2015) "Global action plan on Antimicrobial resistance". Retreived from: https://ahpsr.who.int/publications/i/item/global-action-plan-on-antimicr....
    2. Centers for Disease Control and Prevention (2019) "Antibiotic resistance threats in the United States." Retrieved from: https://www.cdc.gov/drugresistance/biggest-threats.html
    1. Furuno JP; Perencevich EN; Johnson JA; Wright MO; McGregor JC; Morris JG Jr.; Strauss SM; Roghman MC; Nemoy LL; Standiford HC; Hebden JN; Harris AD Methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci co-colonization. Emerg. Infect. Dis 2005, 11, 1539–1544. - PMC - PubMed
    2. Yoon YK; Lee MJ; Ju Y; Lee SE; Yang KS; Sohn JW; Kim MJ Determining the clinical significance of co-colonization of vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus in the intestinal tracts of patients in intensive care units: a case-control study. Ann. Clin. Microbiol. Antimicrob 2019, 18, 28. - PMC - PubMed
    1. Sun Y; Cai Y; Liu X; Bai N; Liang B; Wang R The emergence of clinical resistance to tigecycline. Int. J. Antimicrob. Agents 2013, 41, 110–116. - PubMed
    2. Tian Y; Li T; Zhu Y; Wang B; Zou X; Li M Mechanisms of linezolid resistance in staphylococci and enterococci isolated from two teaching hospitals in Shanghai, China. BMC Microbiol. 2014, 14, 292. - PMC - PubMed
    3. Miller WR; Bayer AS; Arias CA Mechanism of Action and Resistance to Daptomycin in Staphylococcus aureus and Enterococci. Cold Spring Harb. Perspect. Med 2016, 6. - PMC - PubMed
    4. Malbruny B; Canu A; Bozdogan B; Fantin B; Zarrouk V; Dutka-Malen S; Feger C; Leclercq R Resistance to quinupristin-dalfopristin due to mutation of L22 ribosomal protein in Staphylococcus aureus. Antimicrob. Agents Chemother 2002, 46, 2200–2207. - PMC - PubMed
    1. Süssmuth RD; Mainz A Nonribosomal Peptide Synthesis—Principles and Prospects. Angew. Chem. Int. Ed 2017, 56, 3770–3821. - PubMed

Publication types

LinkOut - more resources